[Anti-VEGF treatment in age related macular degeneration]

Intravitreal anti-VEGF (Vascular Endothelial Growth Factor) injections have transformed the prognosis of exudative age-related macular degeneration (AMD) over the past two decades. They are effective in stabilizing the disease, despite the cost of regular injections and follow-up examinations. The advent of biosimilars and second-generation molecules (which allow for longer average treatment intervals) would help to reduce the cost of these therapies. While these treatments have significantly reduced visual impairment due to wet-AMD, they continue to represent a major economic challenge.